Literature DB >> 11403966

Acute and chronic haloperidol treatments increase parkin mRNA levels in the rat brain.

T Nakahara1, L Gotoh, K Motomura, N Kawanami, E Ohta, M Hirano, H Uchimura.   

Abstract

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. We examined the effects of acute and chronic treatment with haloperidol on parkin mRNA expression in the rat brain by reverse transcription-polymerase chain reaction. Acute haloperidol treatment (2 mg/kg) increased parkin mRNA levels in the striatum and nucleus accumbens but not in the medial prefrontal cortex and substantia nigra. Four-week-treatment with haloperidol decanoate (25 mg eq/kg) produced a significant increase in parkin mRNA levels in the striatum without affecting to those in the medial prefrontal cortex, nucleus accumbens and substantia nigra. These results suggest that Parkin may be involved in the haloperidol-induced synaptic plasticity, since Parkin regulates the turnover of the synaptic protein, CDCrel-1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403966     DOI: 10.1016/s0304-3940(01)01880-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  3 in total

1.  Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling.

Authors:  Jianhong Li; Yin Guo; Frederick A Schroeder; Rachael M Youngs; Thomas W Schmidt; Craig Ferris; Christine Konradi; Schahram Akbarian
Journal:  J Neurochem       Date:  2004-09       Impact factor: 5.372

2.  The neuroprotective disease-modifying potential of psychotropics in Parkinson's disease.

Authors:  Edward C Lauterbach; Leonardo F Fontenelle; Antonio L Teixeira
Journal:  Parkinsons Dis       Date:  2011-12-27

3.  Glucocorticoid regulates parkin expression in mouse frontal cortex: implications in schizophrenia.

Authors:  Chirayu D Pandya; Amanda Crider; Anilkumar Pillai
Journal:  Curr Neuropharmacol       Date:  2014-03       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.